599 related articles for article (PubMed ID: 23466964)
1. Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Wong PC; White A; Luettgen J
Hosp Pract (1995); 2013 Feb; 41(1):19-25. PubMed ID: 23466964
[TBL] [Abstract][Full Text] [Related]
2. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
3. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
4. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
5. Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication.
Sadeghi N; Kahn D; Jeske W; Hoppensteadt D; Fareed J
Clin Appl Thromb Hemost; 2013; 19(6):589-99. PubMed ID: 23463187
[TBL] [Abstract][Full Text] [Related]
6. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
[TBL] [Abstract][Full Text] [Related]
7. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
8. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
9. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Herrmann R; Thom J; Wood A; Phillips M; Muhammad S; Baker R
Thromb Haemost; 2014 May; 111(5):989-95. PubMed ID: 24352511
[TBL] [Abstract][Full Text] [Related]
10. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
Ufer M
Thromb Haemost; 2010 Mar; 103(3):572-85. PubMed ID: 20135071
[TBL] [Abstract][Full Text] [Related]
12. Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
Peacock WF
Hosp Pract (1995); 2014 Oct; 42(4):75-82. PubMed ID: 25502131
[TBL] [Abstract][Full Text] [Related]
13. Laboratory monitoring of the non-vitamin K oral anticoagulants.
Blann AD; Lip GY
J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
[No Abstract] [Full Text] [Related]
14. Newer clinically available antithrombotics and their antidotes.
Lévy S
J Interv Card Electrophysiol; 2014 Sep; 40(3):269-75. PubMed ID: 24934756
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
16. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Morales-Vidal S; Schneck MJ; Flaster M; Biller J
Expert Rev Neurother; 2012 Feb; 12(2):179-89; quiz 190. PubMed ID: 22288673
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants].
Roldán Schilling V; Vicente García V
Med Clin (Barc); 2012 Oct; 139 Suppl 2():10-2. PubMed ID: 23498066
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.
Douketis JD
Curr Pharm Des; 2010; 16(31):3436-41. PubMed ID: 20858185
[TBL] [Abstract][Full Text] [Related]
20. A review of oral anticoagulants in patients with atrial fibrillation.
Greenspon AJ
Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
